Finance

Annual Report 2001 of Beximco Pharmaceuticals Limited

Annual Report 2001 of Beximco Pharmaceuticals Limited

It is a broadly described annual report of Beximco Pharmaceuticals Limited in the year of 2001. During the year 2001 Beximco Pharmaceuticals Limited has contributed Taka. 426 million to the national exchequer in the form of import-related taxes, Value Added Tax and Income Tax. During the year, the company attained net sales of Taka. 2,401.24 million as against Taka. 2,452.52 million in 2000. The company earned a pre-tax profit of Taka. 430.42 million as against 422.64 million in 2000. The Company’s gross profit increased by 5.17% and pre-tax profit by 1.84% over last year in absolute terms.

The Board of Directors proposes a dividend @ 10% this year instead of the 20% of the previous year. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Beximco Pharmaceuticals Limited :

  1. Annual Report 2001 of Beximco Pharmaceuticals Limited
  2. Annual Report 2002 of Beximco Pharmaceuticals Limited
  3. Annual Report 2003 of Beximco Pharmaceuticals Limited
  4. Annual Report 2004 of Beximco Pharmaceuticals Limited
  5. Annual Report 2005 of Beximco Pharmaceuticals Limited
  6. Annual Report 2006 of Beximco Pharmaceuticals Limited
  7. Annual Report 2007 of Beximco Pharmaceuticals Limited
  8. Annual Report 2008 of Beximco Pharmaceuticals Limited
  9. Annual Report 2009 of Beximco Pharmaceuticals Limited
  10. Annual Report 2010 of Beximco Pharmaceuticals Limited
  11. Annual Report 2011 of Beximco Pharmaceuticals Limited
  12. Annual Report 2012 of Beximco Pharmaceuticals Limited
  13. Annual Report 2013 of Beximco Pharmaceuticals Limited
  14. Annual Report 2014 of Beximco Pharmaceuticals Limited
  15. Auditors’ Report 2015 of Beximco Pharmaceuticals Limited
  16. Annual Report 2016 of Beximco Pharmaceuticals Limited
  17. Auditors’ Report 2017 of Beximco Pharmaceuticals Limited